Infant Bacterial Therapeutics AB OMXSTO:IBT_B:
Q4 OPERATING INCOME KSEK -20,538* (-37,445)
Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 Mln
Infant Bacterial Therapeutics AB on 6ix
Earlier from Infant Bacterial Therapeutics
- Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Product
- Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Substance
- Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 Mln
- Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3
- IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify
Later from Infant Bacterial Therapeutics
- Infant Bacterial Announces Phase III IBP-9414 Study Results
- Infant Bacterial Therapeutics AB publishes the Annual Report for 2025
- Notice of Annual General Meeting of Infant Bacterial Therapeutics
- Correction: Notice of Annual General Meeting of Infant Bacterial Therapeutics
- IBT_B: Operating loss widened in Q1 2026 as IBP-9414 nears FDA submission and commercialization
Follow Infant Bacterial Therapeutics into a list and get an email when it puts out news.
Follow Infant Bacterial Therapeutics